Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 1Lung Neoplasms 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Carcinoma, Medullary 1Breast Neoplasms 1

Interventions

vandetanib 9Everolimus 4Sorafenib 3sargramostim 2cabozantinib 2Trastuzumab 2Sunitinib 2Gefitinib 2Doxorubicin 2yeast-CEA vaccine 1vatalanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1tipifarnib 1temsirolimus 1tanespimycin 1sacubitril and valsartan sodium hydrate drug combination 1pralsetinib 1pembrolizumab 1pazopanib 1pasireotide 1nintedanib 1motesanib diphosphate 1mercaptoundecahydrododecaborate 1lenvatinib 1fluorodopa F 18 1cixutumumab 1anlotinib 1aldesleukin 1Vorinostat 1Vinorelbine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Carcinoma, Medullary × yeast-CEA vaccine × Clear all
NCT01856920 2024-07-09

QUILT-3.006 for Recurrent Medullary Thyroid Cancer

NantCell, Inc.

Phase 2 Completed
35 enrolled 9 charts

Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡